This preprint is under consideration at SN Comprehensive Clinical Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
guili wang
Affiliated Hospital of Weifang Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Fallopian tube malignancies have been presumed to rare incidence with dismal prognosis. However, recent data suggest that the true incidence of PFTC has been substantially underestimated. Early diagnosis of fallopian tube cancer seems difficult. The routes of metastasis of fallopian tube carcinoma are similar to those of ovarian cancer. Genetic factors are relatively important risk factors for tubal cancer. Poly ADP -ribose polymerase inhibitor is used for BRCA-mutant PFTC. In this artical, we use a rare case of navel metastatic tumor which finally be confirmed that it is originated from fallopian tube to discovered the hereditary factors through genetic testing, and reported this case to provide preventive intervention for the next generation of eugenics and incidence.
Keywords
BRCA, PGD/PGS, Primary high-grade serous Carcinoma of Fallopian Tube, Sister Mary Joseph's nodule
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 17 May, 2021
No community comments so far
Reviewers invited
Invitations sent on 13 May, 2021
Editor assigned
On 02 Apr, 2021
First submitted
On 01 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at SN Comprehensive Clinical Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
guili wang
Affiliated Hospital of Weifang Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 17 May, 2021
No community comments so far
Reviewers invited
Invitations sent on 13 May, 2021
Editor assigned
On 02 Apr, 2021
First submitted
On 01 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Fallopian tube malignancies have been presumed to rare incidence with dismal prognosis. However, recent data suggest that the true incidence of PFTC has been substantially underestimated. Early diagnosis of fallopian tube cancer seems difficult. The routes of metastasis of fallopian tube carcinoma are similar to those of ovarian cancer. Genetic factors are relatively important risk factors for tubal cancer. Poly ADP -ribose polymerase inhibitor is used for BRCA-mutant PFTC. In this artical, we use a rare case of navel metastatic tumor which finally be confirmed that it is originated from fallopian tube to discovered the hereditary factors through genetic testing, and reported this case to provide preventive intervention for the next generation of eugenics and incidence.
Figure 1
Loading...